​Estudios pediátricos (<21 años de edad)

1. Protocol 045 – Westat Immune Globuline
2. ACTG 138 – A Trial of Two doses of 2’, 2’-Dideoxycytidine (ddc) in the treatment of children with symptomatic HIV Infection Who are Intolerant of ZDV and/or who show progressive disease while on ZDV.
3. Protocol 327- Trial of Stavudine (D4T) plus Didanosine (DDI) in Children on long term – stavudine monotherapy and Stavudine vs Stavudine plus Didanosine in Children on Long-term Zidovudine Therapy.
4. Protocol  338 – A Phase II Rolling arm master Protocol (PRAM) of Novel Antiretroviral Therapy in stable, experienced, HIV-Infected Children PRAM 1: ZDV+3TC Vc. D4T+ Ritonavir Vs. ZDV+3TC+Ritonavir, PRAM 1, Step 2: d4T+ Nevirapine; PRAM 1 Step 3: D4T+  Indinavir Vs. ZDV + 3TC + Indinavir.
5. Protocol  273 – A Phase I/II Study of HIVIG in slowing progression of disease in HIV-Infected Children.
6. Protocol 152 – A randomized Comparative Trial of Zidovudine vs. 2`, 3`-Dideoxyinosine (ddI) vs. Plus ddI in Symptomatic HIV-Infected Children.
7. Protocol 254 – Randomized Phase II/III, Two-Armed Study of Micronized- Atovaquone and Azithromycin (AT/AZ) as compared to (TMP/SMX) in the Prevention of serious Bacterial Infections when used in children aged 2-19 years with HIV infections.
8. Protocol 247- A randomized, Double –Blind Controlled Study of An Increased Caloric density Infant Formula and Its Effect On Growth and Nutritional Status In HIV-Infected Infants.
9. Protocol 300 – A Randomized Comparative Study of Combined Zidovudine Plus DDI In Symptomatic HIV-1 Infected Children.
10. Protocol 128 – A Randomized Trial to Evaluate the Safety and Tolerance of High versus Low Dose Zidovudine Administered to Children with Human Immunodeficiency Virus
11. Protocol 245 - A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents with Advanced HIV Disease
12. Protocol 144 - A Randomized Comparative Trial of Two Doses of Two Doses of 2’, 3’- Dideoxyinosine (ddI) in Children with Symptomatic HIV Infection Who Are Either Unresponsive to Zidovudine and/ or Who Are Intolerant to Zidovudine
13. Protocol 240- A Randomized, Comparative Trial of Zidovudine (ZDV) Versus 2’, 3’-Didehydro-3Deoxythymidine (d4T) in Children with HIV-Infection
14. Protocol 218 – A Placebo Controlled, Phase I Clinical Trial to Evaluate the Safety and Immunegenecity of Recombinant Envelope Proteins of HIV-1 GP160 and GP120 in Children ≥ 1 month Old with Asymptomatic HIV Infection
15. PACTG 219 – Pediatric Late Outcomes Protocol
16. PACTG 219C - Pediatric Late Outcomes Protocol: Prospective, Longitudinal Data Collection For Long-Term Follow-Up
17. Mutagenicity – A study of potential mutagenicity of zidovudine/nucleoside analogue treatment in perinatal HIV prophylaxis.
18.  Protocol 190 – A Phase II Study to Evaluate Pharmacokinetics, Safety, Tolerance and Activity of Dideoxycytidine (ddc) Administered In Combination with Zidovudine (ZDV) in Stable, ZDV Treated Pediatric Patients with HIV Infection.
19. Protocol 182 - A Phase III Study to Evaluate the Safety, Tolerance and Efficacy of Early Treatment with Zidovudine (ZDV) in Asymptomatic Infants with HIV Infection
    
20. Protocol 382 - A Phase I/II, Open-Label, AUC- Controlled Study To Determine the Pharmacokinetics, Safety, Tolerability and Antiviral Activity of DMP In Combination with Nelfinavir in Children.
21. Protocol 377 - A Phase II Rolling Arm Master Protocol of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children
22. Protocol 395 - A Multicenter, Open Labeled, 48-Week Study to Investigate The Safety, Pharmacokinetics, and Efficacy of Indinavir in Combination with Stavudine and Lamivudine in Pediatric Patients with HIV-1 Infection
23. Protocol 397 - A Randomized Trial of Two Saquinavir-Containing Combination Treatment Regimens in Children with HIV Infection
24. Protocol NV14610A - An Open Label Safety Program for the Use of Dideoxycytidine (ddc) in Pediatric Patients with Symptomatic HIV Infection Who have Failed or are Intolerant to ZDV Monotherapy, or who have Completed other ddc Protocols, or are Ineligible for Other Ongoing Clinical Studies.
25.  ATN 024 -A Randomized, Open-Label Trial of Three Hepatitis B Vaccination Schemas in HIV Positive Youth
26. ATN 048 - Correlates of HBV-Specific B Cell Memory Following Vaccination in HIV-Infected Adolescents and HIV-Uninfected Adolescents a Substudy of ATN 048 and ATN 024
27.  ATN 061 – Preservation and Expansion of T-Cell subsets following HAART De-intensification to Atazanavir/ritonavir in Adolescents and Young adults with CD4=" T" Cells >350 cells/mm³ initiating HAART
28. ATN 109 - A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth with HIV Infection Being Treated with Tenofovir-Containing Combination Antiretroviral Therapy.
29. PACTG P1006- The Effects of Highly Antiretroviral Therapy (HAART) on the Recovery of Immune Function in HIV Infected Children and Young Adult
30. Protocol P1024 - Evaluation of the Immunogenicity of Pneumococcal Conjugate Vaccine and Routine Pediatric Immunizations in HIV- Infected Children Treated with Highly Active Antiretroviral Therapy (HAART)
    
31. Protocol P1013 - A Phase I/II Trial of Ritonavir and Indinavir in Children Failing Other Antiretroviral Therapy
32. Protocol P1020A - Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS 232632) in Combination Regimens in Antiretroviral Therapy (ART)- Naïve and Experienced HIV-Infected Infants, Children and Adolescents
33. Protocol P1021 – An Open-Label Study To Evaluate The Safety, Tolerance, Anti-Viral Activity and Pharmacokinetics of Emtricitabine in Combination With Efavirenz and Didanosine in a Once Daily Regimen In HIV Infected Infected Antiretroviral Therapy Naïve or Very Limited Antiretroviral Exposed Pediatric Subjects.
34. PACTG P1030 - A Phase I/II Study of Lopinavir/Ritonavir (LPV/RTV) in HIV-1 Infected Infants < 6 months of age
35. PACTG P1034 - A Comparative Trial of Protease-Containing and Protease Sparing HAART Regimens in HIV-Infected Adolescents with an Evaluation of Therapeutic Drug Monitoring
36. P1038 - A Phase I /II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir with or without Saquinavir in HIV Infected Pediatric Subjects Previously Treated with Protease Inhibitors
37. PACTG P1042s - Cognitive, Behavioral, and Psychological Correlates of Medication adherence in Children and Adolescents with HIV-1 Infection
38. PACTG P1043 - Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission
39. PACTG P1045 - Prevalence of Morphologic and Metabolic Abnormalities in Vertically HIV-Infected and Uninfected Children and Youth
40. PACTG P1051 - Multiple-dose, open-label, randomized, safety and pharmacokinetic study of tipranavir in combination with low-dose ritonavir in HIV-infected pediatric patients
41. PACTG P1053 - A Phase II, Randomized, Open-Label Study To Evaluate The Safety And Effectiveness Of Two Antiretroviral Therapeutic Strategies:  A Dual Pi-Based-HAART Regimen Versus A Multi-NRTI-Art Regimen, In Art-Experienced Children And Youth Who Have Experienced Virologic Failure
42. PACTG P1055 -Psychiatric Co-Morbidity in Perinatally HIV-Infected Children and Adolescents.
43. PACTG P1057 - A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (Flumist) in HIV-Infected Children and Adolescents
44. IMPAACT P1058 -Intensive Pharmacokinetic Studies of Antiretroviral Drug Combinations in Children
45. P1058A - Intensive PK studies of ARV combinations.
46. PACTG P1061s: Evaluation of Immunologic Memory Following Pneumococcal, Hepatitis B, and Measles Vaccination in HIV-Infected Children Treated with Highly Active Antiretroviral Therapy (HAART)
47. P1047 - Safety and Immunogenicity of Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18 l1 Virus-Like Particle (VLP)] (Gardasil^®) Vaccine in HIV-Infected Children > 7 to < 12 Years of Age
48. Gilead GS-US-104-0352 - A Phase III, Randomized, Open Label Study Comparing the Safety and Efficacy of Switching Stavudine or Zidovudine to Tenofovir Disoproxil Fumarate versus Continuing Stavudine or Zidovudine in Virologically Suppressed HIV-Infected Children Taking Highly Active Antiretroviral Therapy
49. A4001031 – An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic, Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected Children 2 < 18 years of age.
50. AI424451 – A Prospective single arm, open-label, international, multicenter study to evaluate the safety, efficacy and pharmacokinetics of atazanavir powder boosted with ritonavir liquid with an optimized NRTI background therapy, in HIV-Infected, Antiretroviral, Naïve and Experienced Pediatric subjects greater than or equal to 3 months to less than 8 years (The Prince Study).
51. 390 - A Phase II/III Randomized, Open-Label Study of Combination Antiretroviral Regimens and Treatment-Switching Strategies in HIV-1-Infected Antiretroviral Naive Children >30 Days and <18 Years of Age
52. P1065 - Phase I/II, Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Children and Youth and Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth
53. P1066 - A Phase I/II, Multicenter, Open-Label, Noncomparative Study of the International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Group to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of Raltegravir (Insentress^TM, MK-0518) in HIV-1 Infected Children and Adolescents
54. P1074 - A Prospective Surveillance Study of Long-Term Outcomes in HIV-infected Infants, Children and Adolescents
55. IMPAACT P1076 Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-Infected Children and Adolescents with Low Bone Mineral Density
56. P1080 A Pilot Study of Psychiatric and Antiretroviral Medication Concentrations in HIV-1 Infected and Uninfected Children and Adolescents
57. P1083 - A Phase II/III Trial of Lopinavir/Ritonavir Dosed According to the WHO Pediatric Weight Band Dosing Guidelines
58. P1085 - Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents
59. IMPAACT P1088 A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Perinatally Infected Children and Youth
60. P1089 – A laboratory study to assess the immunogenicity of three licensed Influenza A (H1N1) 2009 Monovalent Vaccines In HIV-1 Perinatally Infected Children and Youth
61. TMC125-TiDP35 - A Phase II, Open Trial Label to Evaluate the Safety, Tolerability and Antiviral Activity of TMC125 in Antiretroviral Experienced HIV-1 Infected Children and Adolescents.
62. P1094 - Evaluation of 3TC or FTC Monotherapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-Adherent Children, Adolescents and Young Adults Who are Failing HAART and have the M184V Mutation
63. P1096 – Phase 1 Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-passaged cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
64. P1097altegravir Pharmacokinetics and Safety in Neonates
65. IMPAACT P1110, A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at High Risk of Acquiring HIV-1 Infection
66. Biocollections 2010-8152 A multi-site, point in time, prospective blood collection protocol, in order to obtain samples from HIV Positive Pediatric D/P’s (donor/participants)
67. PHACS PH200 Adolescent Master Protocol
68. PHACS PH101 - Newborn Evaluation for Effects of Maternal Tenofovir Use During Pregnancy - A Multi-Center Substudy of the Pediatric HIV/AIDS Cohort Study (PHACS) - Surveillance Monitoring for ART Toxicities Study in HIV-uninfected Children Born to HIV-infected Women (SMARTT) Protocol
69. PHACS PH202 - Role of oral microbiata in causing neurocognitive deficits in HIV infected children to the PHACS Adolescent at PHACS AMP sites.
70. PHACS PH203 - Pulmonary Complications in the Pediatric HIV/AIDS Cohort Study - Adolescent Master Protocol (AMP)
71. Pfizer A3191193 - Trial of Pediatric Patients With Familial Adenomatous Polyposis (FAP) (CHIP)
72. V114-027- A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants”.
73. V114-029- A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 4-dose Regimen of V114 in Healthy Infants
74. B7471011A - Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
75. IMPAACT P1111, A Phase I/II, Open-Label Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naïve HIV-1 Infected Children, < 12 Years of Age
76. IMPAACT P1115, Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study
77. PSK00008 - Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants. 
    

Estudios en adultos (> 21 años de edad)

1. ACTG 200 - A Phase III Randomized Trial of Topical Vaginal Fluorouracil Manintenance Therapy vs. observation after standard treatment for high grade cervical dysplasia in HIV-infected women.
2. ACTG 288 - Follow up of women participating in ACTG 076
3. Protocol 321 - Phase I study of tolerance and Pharmacokinetics of 1592U89 with standard Zidovudine (ZDV) therapy in neonates born to HIV-1 Infected Women.
4. ACTG 255 – Study of Perinatal Transmission of Zidovudine Resistant HIV Among Pregnant Women Treated with Zidovudine.
5. Protocol 293 – A Randomized Phase III of Oral Isotretinoin vs Observation for Low Grade Cervical Dysplasia in HIV-Infected Women.
6. Protocol 317- Effect of Oral and Injectable Contraceptives (Norethindrone/Ethinyl Estradiol, Medroxyprogesterone Acetate) and Gender on Plasma and Intacellular Zidovudine Pharmacokinetics.
7. Protocol 329 - A Randomized, Double Blind, Placebo-Controlled, Phase I/II trial of Nandrolone Decanoate in Women with HIV-Associated Weight Loss
8. Protocol 332 - A Phase I/II Open Label Study To Evaluate The Safety. Tolerance Pharmacokinetics Of Stavudine (d4T) In Combination with Lamivudine (3TC) HIV-1 Infected Pregnant Women And Their Infants.
9. ACTG 367 - Chart abstraction of HIV Infected pregnant women and their infants receiving care or consultation at PACTG Obstetrical Site.
10. Protocol 249 (949)- a Phase I Trial To Evaluate Didanosine (ddI) In HIV-1 Infected Pregnant Women
11. Protocol 403 – A Phase I Trial to Evaluate Didanosine in HIV-1 Pregnant Women.
12. Protocol 394 - A Phase I Study of the Tolerance and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and their Infants
13. ACTG A5029, Assessment of Prevalence and Persistence of Human Papilloma Virus DNA in HIV-Infected Women who are antiretroviral naïve and have initiated HAART.
14. ACTG A5084, Evaluation of Metabolic Complications Associated with antiretroviral medications in HIV-1 Infected Pregnant Women.
15. A5150, A prospective observational study of virologic and immunologic changes in HIV-infected women during the postpartum period
16. A5188, A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and oral contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir
17. A5240 – A Phase II Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Human Papillomavirus Vaccine in HIV-1-Infected Females
18. A5241 - The Optimized Treatment that Includes or Omits NRTIs (OPTIONS) Trial: A Randomized Strategy Study for HIV-1-Infected Treatment-Experienced Subjects Using the cPSS to Select an Effective Regimen
19. ACTG A5283 An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA) and Lopinavir/ritonavir (LPV/r) and of the Effects of DMPA on Cellular Immunity and Regulation in HIV-Infected Women
20. P1022 – Randomized Trial of Protease Inhibitor including vs protease inhibitor sparing regimens for women who initiate therapy of HIV Infection During Pregnancy.
21. A5257 – A Phase III Comparative Study of Three Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Sparing Antiretroviral Regimens for Treatment-Naïve HIV-1-Infected Volunteers (The ARDENT Study: Atazanavir, Raltegravir or Darunavir with Emtricitabine/Tenofovir for Naïve Treatment)
22. IMPAACT 1077HS, HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)
23. GSK 201147 A Phase IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose combination of abacavir/dolutegravir/ lamivudine from current antiretroviral regimen compared with continuation of the current antiretroviral regimen in HIV-1 infected adults who are virologically suppressed.
24. START - Strategic Timing of Antiretroviral Treatment
25. Biocollections 2016-75173, A Multi-Site, Point in Time, Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) with or suspected of having Zika, Dengue and/or Chikungunya Virus
26. Prospective Cohort Study of HIV and Zika in Infants and Pregnancy, (HIV ZIP)
27. VRC 704 - Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety And Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults 
28. VRC 705 – A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents.
29. MV-CHIK 206 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults
30. Lilly J1I-MC-GZBF A Phase 2 Study of Once-Weekly LY3437943 Compared with Placebo in Participants Who Have Obesity or Are Overweight with Weight-Related Comorbidities
31. V116-003 - A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 

Estudios Perinatales

1. ACTG  076 - A Randomized Placebo-Control Trial to Evaluate the efficacy, Safety and tolerance of Zidovudine for the prevention of Maternal-Fetal HIV Transmission.
2. ACTG 250 - A Phase I study of safety and pharmacokinetics of nevirapine in HIV infected pregnant women and neonates born to HIV infected mothers
3. ACTG 085 - Randomized, Double Blind, Control Study of the Use of HIVIG for the Prevention of Maternal-Fetal Transmission in Pregnant Women and Newborns Receiving Zidovudine.
4. ACTG 296 - Intracellular pharmacokinetics of ZDV triphosphate in maternal and infant cord blood mononuclear cells.
5. ACTG 185 - Randomized, Double blind, Control Study of the use of HIVIG for the prevention of Maternal – Fetal Transmission in pregnant Women and Newborns receiving Zidovudine.
6. Protocol 316 - A Phase III Randomized, Blinded Study Of Nevirapine For The Prevention of Maternal-Fetal Transmission In Pregnant Women
7. Protocol 353 – A Phase I Trial Of the Safety and Tolerance, And Pharmacokinetics Of Oral Nelfinavir (Viracept) Co-Administered with Zidovudine (ZDV) And Lamivudine (3TC) In HIV Infected Pregnant Women and Their Infants.
8. Protocol ACTG 386 – A Phase I Trial of the Safety and Pharmacokinetics of Fortovase (Saquinavir–SGC) Co-Administered with Low Dose RTV, ZDV and 3TC in HIV Seropositive Pregnant Women During Gestation and Postpartum, and in their Infants Post Maternal Dosing
9. ACTG A5084, Evaluation of Metabolic Complications Associated with antiretroviral medications in HIV-1 Infected Pregnant Women.
10. P1025 - Perinatal Core Protocol
11. P1031 – Mother-infant rapid intervention at delivery
12. P1039 – A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir vs Zidovudine/Lamivudine/lopinavir/Ritonavir in the prevention of perinatal transmission of HIV.
13. P1081, A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Three Different Potent Regimens in HIV-infected Women Initiating Triple Antiretroviral Regimens between 28 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission
14. IMPAACT P1086, A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 Infected Pregnant Women, Version 1.0, dated September 01, 2009
15. An Observational Study of Hepatitis C Virus in Pregnancy
16. IMPAACT P1112, Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, a Potent Anti-HIV Neutralizing Monoclonal Antibody, in HIV-1 Exposed Infants